Abstract
Given significant genetic, molecular, and phenotypic overlaps, researchers have begun to investigate whether targeted treatments for Fragile X Syndrome (FXS) could also be beneficial for patients with Autism Spectrum Disorder (ASD). For example, low-dose sertraline, an SSRI, was used in two recent controlled trials in children with FXS and ASD. The first trial recruited 52 children with FXS, 32 of which were also diagnosed with ASD; the second trial recruited 58 children with non-syndromic ASD. One focus of the present study is to compare the response to sertraline between the FXS-associated ASD and non-syndromic ASD groups. Another focus is to compare baseline ASD-related characteristics between the groups and review these differences within the context of recent literature comparing these populations. Our comparison showed more severe ASD profiles in children with non-syndromic ASD vs. FXS-associated ASD. Regarding response to sertraline, the FXS-ASD group displayed significant improvements in language development, while the non-syndromic group did not show any significant improvements. One possible explanation for this differential response is the distinct anxiety profiles that are seen in these two groups. The heightened an...Continue Reading
References
Jan 26, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Julie A Dopheide
Jul 11, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Aaron W GrossmanWilliam T Greenough
Oct 10, 2006·Neuromolecular Medicine·Dorothy E Grice, Joseph D Buxbaum
Nov 16, 2007·Development·Katarzyna BartkowskaFreda D Miller
Nov 11, 2009·Developmental Psychology·Rhiannon Luyster, Catherine Lord
Jul 2, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Patrizia BianchiRenata Bartesaghi
Jul 21, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Lulu W WangRandi J Hagerman
Apr 13, 2011·Journal of Neurodevelopmental Disorders·Elizabeth Berry-KravisCrystal Hervey
Jun 11, 2011·Neuron·Sarah R GilmanDennis Vitkup
Apr 13, 2012·Nature·Brian J O'RoakEvan E Eichler
Apr 24, 2012·Neuroscience·C X He, C Portera-Cailliau
May 1, 2012·Neuron·Ivan IossifovMichael Wigler
Jun 26, 2012·American Journal of Human Genetics·Rui LuoDaniel H Geschwind
Aug 31, 2012·Autism Research and Treatment·Tri Indah WinarniRandi J Hagerman
Dec 4, 2012·Journal of the American Academy of Child and Adolescent Psychiatry·Jason J WolffJoseph Piven
Jan 15, 2014·Journal of Autism and Developmental Disorders·Andrea McDuffieLeonard Abbeduto
Jan 21, 2014·Human Genetics·Regina WaltesAndreas G Chiocchetti
Apr 29, 2014·American Journal of Human Genetics·Dalila PintoStephen W Scherer
Sep 6, 2014·Seminars in Neurology·Timothy W Yu, Elizabeth Berry-Kravis
Nov 2, 2014·Frontiers in Genetics·Leonard AbbedutoAngela John Thurman
Aug 26, 2016·Journal of Developmental and Behavioral Pediatrics : JDBP·Laura Greiss HessRandi J Hagerman
Aug 18, 2017·Pediatrics·Walter E KaufmannElizabeth Berry-Kravis
Nov 2, 2018·Journal of Autism and Developmental Disorders·Leonard AbbedutoJane E Roberts
Nov 16, 2018·Journal of Autism and Developmental Disorders·Jordan EzellJane Roberts
Dec 7, 2018·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Hui GuoEvan E Eichler
Jan 23, 2019·Journal of Neurodevelopmental Disorders·Michael P HongCraig A Erickson
Nov 30, 2019·Frontiers in Psychiatry·Laura A PotterRandi J Hagerman